Aquestive Therapeutics Completes $70 Million Debt Refinancing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
Aquestive Therapeutics (AQST) PT Raised to $12 at H.C. Wainwright
July 16, 2019 8:10 AM EDTH.C. Wainwright analyst Raghuram Selvaraju raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst commented, "Yesterday afternoon, Aquestive Therapeutics announced that it has completed a private placement of $70M of 12.5% senior secured notes due June 2025 and warrants, and refinanced its existing credit facility. The indenture governing the notes provides opportunity to issue up to $30M of... More



